Physiologically, mesothelin (MSLN) exhibits low expression in mesothelial tissues, such as pleura, peritoneum and pericardium, but high expression in various cancers, including mesothelioma, pancreatic, lung, ovarian cancers, acute myeloid leukemia and triple negative breast cancers. Here, MSLN is linked to cancer.